BR112018011261A2 - ?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação? - Google Patents

?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação?

Info

Publication number
BR112018011261A2
BR112018011261A2 BR112018011261A BR112018011261A BR112018011261A2 BR 112018011261 A2 BR112018011261 A2 BR 112018011261A2 BR 112018011261 A BR112018011261 A BR 112018011261A BR 112018011261 A BR112018011261 A BR 112018011261A BR 112018011261 A2 BR112018011261 A2 BR 112018011261A2
Authority
BR
Brazil
Prior art keywords
checkpoint inhibitor
individual
methods
treating cancer
prolonging
Prior art date
Application number
BR112018011261A
Other languages
English (en)
Portuguese (pt)
Inventor
Law Che-Leung
Field Jessica
Okeley Nicole
Senter Peter
Gardai Shyra
Original Assignee
Seattle Genetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Genetics Inc filed Critical Seattle Genetics Inc
Publication of BR112018011261A2 publication Critical patent/BR112018011261A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
BR112018011261A 2015-12-04 2016-12-02 ?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação? BR112018011261A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562263228P 2015-12-04 2015-12-04
US201662308583P 2016-03-15 2016-03-15
US201662321857P 2016-04-13 2016-04-13
PCT/US2016/064783 WO2017096274A1 (en) 2015-12-04 2016-12-02 Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor

Publications (1)

Publication Number Publication Date
BR112018011261A2 true BR112018011261A2 (pt) 2018-11-21

Family

ID=58797961

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018011261A BR112018011261A2 (pt) 2015-12-04 2016-12-02 ?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação?

Country Status (13)

Country Link
US (1) US20180353524A1 (https=)
EP (1) EP3383404A4 (https=)
JP (1) JP6906520B2 (https=)
KR (1) KR20180086233A (https=)
CN (1) CN108289903B (https=)
AU (1) AU2016362993A1 (https=)
BR (1) BR112018011261A2 (https=)
CA (1) CA3005997A1 (https=)
EA (1) EA201891340A1 (https=)
IL (1) IL259479B (https=)
MX (1) MX385283B (https=)
SG (2) SG10202005298RA (https=)
WO (1) WO2017096274A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2608796T3 (en) 2010-08-05 2019-03-18 Seattle Genetics Inc Inhibition of protein fucosylation in vivo using fucose analogues
SG10201912663YA (en) 2016-10-11 2020-03-30 Agenus Inc Anti-lag-3 antibodies and methods of use thereof
JP7245177B2 (ja) * 2017-06-07 2023-03-23 シージェン インコーポレイテッド 低減した表面フコシル化を有するｔ細胞、及びそれを作製及び使用する方法
WO2019075449A1 (en) * 2017-10-13 2019-04-18 H. Lee Moffitt Cancer Center And Research Institute, Inc. FUCOSYLATION AND IMMUNOSURVEILLANCE OF MELANOMA
JP2021534196A (ja) 2018-08-23 2021-12-09 シージェン インコーポレイテッド 抗ｔｉｇｉｔ抗体
SG11202106481SA (en) * 2018-12-19 2021-07-29 Seagen Inc Controlled fucosylation of antibodies
WO2021034774A1 (en) * 2019-08-16 2021-02-25 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN111973749B (zh) * 2020-09-07 2023-03-21 威海人生药业集团股份有限公司 一种抗肿瘤免疫治疗的药物组合物
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022221766A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Fucosylation and immune modulation in cancer
CN113274502B (zh) * 2021-05-05 2023-01-03 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 用于特定型三阴乳腺癌免疫治疗的组合物
WO2022236017A1 (en) * 2021-05-06 2022-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. L-fucose and anti-androgen receptor therapy for treatment of cancer
CN113413465B (zh) * 2021-06-15 2022-06-03 北京大学 岩藻糖基化抑制剂在抗癌导致炎症中的应用
CN115466297B (zh) * 2022-08-25 2023-07-07 青岛农业大学 L-岩藻糖的应用以及动物饲料
WO2024077106A2 (en) * 2022-10-04 2024-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Leveraging l-fucose-mediated signaling to induce monocyte-derived dendritic cell polarization
WO2024191807A1 (en) 2023-03-10 2024-09-19 Seagen Inc. Methods of treating cancer with anti-tigit antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2608796T3 (en) * 2010-08-05 2019-03-18 Seattle Genetics Inc Inhibition of protein fucosylation in vivo using fucose analogues
KR20160093012A (ko) 2013-11-05 2016-08-05 코그네이트 바이오서비시즈, 인코포레이티드 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물

Also Published As

Publication number Publication date
EP3383404A4 (en) 2019-07-31
EP3383404A1 (en) 2018-10-10
IL259479B (en) 2022-03-01
WO2017096274A1 (en) 2017-06-08
SG11201804263PA (en) 2018-06-28
JP2019501145A (ja) 2019-01-17
US20180353524A1 (en) 2018-12-13
JP6906520B2 (ja) 2021-07-21
CN108289903B (zh) 2021-08-03
MX385283B (es) 2025-03-18
SG10202005298RA (en) 2020-07-29
AU2016362993A1 (en) 2018-07-12
MX2018006674A (es) 2018-11-09
KR20180086233A (ko) 2018-07-30
CN108289903A (zh) 2018-07-17
CA3005997A1 (en) 2017-06-08
EA201891340A1 (ru) 2018-11-30
IL259479A (en) 2018-07-31

Similar Documents

Publication Publication Date Title
BR112018011261A2 (pt) ?métodos para tratar câncer, para inibir a proliferação de um tumor e para iniciar, intensificar ou prolongar os efeitos de um inibidor de ponto de verificação ou permitir a um indivíduo responder a um inibidor de pontos de verificação?
MX2019011061A (es) Compuestos útiles en el tratamiento o prevención de un trastorno mediado por la proteína arginina metil-transferasa 5 (prmt5).
BR112017000672A2 (pt) composições para tratamento de câncer utilizando antagonistas de ligação de eixo pd-1 e inibidores de mek
IL262849B (en) Use of glutamate modulating factors in cancer immunotherapy
CL2018001134A1 (es) Composiciones y métodos para inhibir la actividad arginasa
MX376078B (es) Combinación de un antagonista de pd -1 y dinaciclib para usarse en el tratamiento de cáncer.
BR112016018555A8 (pt) Ciclopropilaminas como inibidores de lsd1, seu uso, composição farmacêutica que os compreende e método de inibição de lsd1
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX2017013802A (es) Métodos para tratar el cáncer.
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
MX2016014253A (es) Inhibidores de desmetilasa-1 especifica de lisina.
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
MX2018008346A (es) Terapia de combinación de virus oncológico e inhibidor de punto de control.
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
BR112017018872A2 (pt) combinação de um antagonista pd-1 e eribulina para tratamento de câncer
BR112022009631A2 (pt) Combinações de inibidores de dgk e antagonistas do ponto de checagem
MX385315B (es) Composiciones y metodos para inhibir actividad de arginasa.
MX385674B (es) Composiciones para modular la expresion de c9orf72.
BR112018069927A2 (pt) terapia de câncer com um vírus oncolítico combinado com um inibidor de ponto de verificação
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
MX374924B (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2016005980A (es) Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal.
MX377351B (es) Metodos para el tratamiento de cancer utilizando inhibidores b-raf e inhibidores de punto de control inmunologico
BR112017002263A2 (pt) inibidores de proteína cinase c e métodos de uso dos mesmos
MX2020000386A (es) Inhibidores heterociclicos de la cinasa atr.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B25E Requested change of name of applicant rejected

Owner name: SEATTLE GENETICS, INC. (US)

Free format text: INDEFERIDO O PEDIDO DE ALTERACAO DE NOME CONTIDO NA PETICAO 870210118851 DE28/12/2021 DEVIDO AO DESPACHO PUBLICADO NA RPI 2660 DE 28/12/2021.